| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | EVP, Chief Operating Officer | Chief Operating Officer
3 companies
Last Andrew J. is a Director at IMDX, with reported holdings spanning 3 companies. Recent filings cover 4 purchases and 4 sales. Those positions are worth an estimated $2.9M at current prices.
Our model assigns Last Andrew J. a below-average insider score of 49/100, based on 3 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of -10.0%.
Last Andrew J.'s largest disclosed position is in BIO as EVP, Chief Operating Officer, worth about $2.5M. The recent filings there lean toward selling, a net 5,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 6, 2024 | BIO Bio-Rad Laboratories, Inc. | EVP, Chief Operating Officer | Sale+OE | 3,000 | $329.94 | $989,815.20 | -28.4% | -2.2% | -10.4% | |
| Aug 17, 2022 | IMDX Insight Molecular Diagnostics Inc. | Director | Buy | 20,000 | $0.87 | $17,400.00 | +39.9% | -53.3% | -80.7% | |
| Sep 1, 2021 | BIO Bio-Rad Laboratories, Inc. | EVP, Chief Operating Officer | Sale+OE | 2,000 | $813.10 | $1,626,203.06 | -60.9% | -7.6% | -40.3% | |
| Jul 26, 2018 | IMDX Insight Molecular Diagnostics Inc. | Director | Buy | 6,993 | $0.00 | - | New | - | - | |
| Nov 13, 2017 | PGEN Precigen, Inc. | Chief Operating Officer | Buy | 2,000 | $12.10 | $24,200.00 | +100.0% | - | - | |
| Aug 14, 2017 | PGEN Precigen, Inc. | Chief Operating Officer | Buy | 2,000 | $19.99 | $39,980.00 | New | - | - |